Nanotherapeutic and a method of oxidative dehydrogenation built on hierarchical silica composites

A nanotherapeutic, comprising:

• an antitumor agent;
• a fluorophore;
• a magnetic resonance imaging moiety;
• and
• a hierarchical silica composite,
• wherein the hierarchical silica composite, comprises:
• a stereoregular MCM-41 ordered arrangement of uniformly-sized mesopores with diameters in a range of 10-50 nm and mesopore walls having a thickness of 3 to about 5 nm;
• and
• a stereoregular ZSM-5 ordered arrangement of uniformly-sized micropores with diameters of less than 2 nm located within the mesopore walls of the stereoregular MCM-41;
• and
• a silane coating that coats at least a portion of a surface of the hierarchical silica composite,
• wherein the magnetic resonance imaging moiety is incorporated into a lattice of the hierarchical silica composite by isomorphous substitution,
• wherein the antitumor agent is located inside the mesopores of the hierarchical silica composite,
• wherein an amount of the antitumor agent is in a range of 10-20 w.t.%,
• wherein an amount of the hierarchical silica composite is in a range of 15-70 w.t.%,
• wherein an amount of the fluorophore is in a range of 5-7.5 w.t.%, and
• wherein an amount of the magnetic resonance imaging moiety is in a range of 15-25 w.t.%, all of which are relative to the total weight of the nanotherapeutic.